Insurance continuity and human papillomavirus vaccine uptake in Oregon and California federally qualified health centers.

Stuart Cowburn, Matthew Carlson, Jodi Lapidus, John Heintzman, Steffani Bailey, Jennifer DeVoe
Author Information
  1. Stuart Cowburn: Stuart Cowburn is with OCHIN, Inc., Portland, OR. Matthew Carlson is with the Department of Sociology, Portland State University, Portland. Jodi Lapidus is with the Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland. John Heintzman, Steffani Bailey, and Jennifer DeVoe are with the Department of Family Medicine, Oregon Health & Science University, Portland.

Abstract

OBJECTIVES: We examined the association between insurance continuity and human papillomavirus (HPV) vaccine uptake in a network of federally qualified health clinics (FQHCs).
METHODS: We analyzed retrospective electronic health record data for females, aged 9-26 years in 2008 through 2010. Based on electronic health record insurance coverage information, patients were categorized by percent of time insured during the study period (0%, 1%-32%, 33%-65%, 66%-99%, or 100%). We used bilevel multivariable Poisson regression to compare vaccine-initiation prevalence between insurance groups, stratified by race/ethnicity and age. We also examined vaccine series completion among initiators who had at least 12 months to complete all 3 doses.
RESULTS: Significant interactions were observed between insurance category, age, and race/ethnicity. Juxtaposed with their continuously insured peers, patients were less likely to initiate the HPV vaccine if they were insured for less than 66% of the study period, aged 13 years or older, and identified as a racial/ethnic minority. Insurance coverage was not associated with vaccine series completion.
CONCLUSIONS: Disparities in vaccine uptake by insurance status were present in the FQHCs studied here, despite the fact that HPV vaccines are available to many patients regardless of ability to pay.

References

  1. Ann Fam Med. 2011 Jul-Aug;9(4):351-8 [PMID: 21747107]
  2. JAMA Pediatr. 2014 Jan;168(1):76-82 [PMID: 24276343]
  3. J Am Board Fam Med. 2008 Jan-Feb;21(1):31-7 [PMID: 18178700]
  4. MMWR Recomm Rep. 2011 Jan 28;60(2):1-64 [PMID: 21293327]
  5. Am J Epidemiol. 2005 Jan 1;161(1):81-8 [PMID: 15615918]
  6. J Community Health. 2010 Dec;35(6):645-52 [PMID: 20336354]
  7. Am J Epidemiol. 2010 Feb 1;171(3):357-67 [PMID: 20047978]
  8. J Womens Health (Larchmt). 2010 Dec;19(12):2167-74 [PMID: 21039233]
  9. Vaccine. 2012 Mar 16;30(13):2368-75 [PMID: 22108490]
  10. Prev Chronic Dis. 2013 Oct 24;10:E173 [PMID: 24157076]
  11. J Adolesc Health. 2010 Dec;47(6):596-9 [PMID: 21094437]
  12. Am J Prev Med. 2010 May;38(5):525-33 [PMID: 20409501]
  13. Med Care. 2009 Apr;47(4):431-9 [PMID: 19330890]
  14. Vaccine. 2012 Mar 30;30(16):2676-82 [PMID: 22342548]
  15. Curr Opin Obstet Gynecol. 2012 Oct;24(5):305-10 [PMID: 22781077]
  16. Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1463-72 [PMID: 21602307]
  17. Occup Environ Med. 2008 Jul;65(7):481, 501-6 [PMID: 18562687]
  18. Pediatrics. 2011 Jan;127(1):77-84 [PMID: 21149425]
  19. Lancet. 2007 Sep 8;370(9590):890-907 [PMID: 17826171]
  20. Vaccine. 2009 Nov 16;27(49):6840-4 [PMID: 19765398]
  21. MMWR Morb Mortal Wkly Rep. 2013 Aug 30;62(34):685-93 [PMID: 23985496]
  22. Prev Med. 2009 May;48(5):426-31 [PMID: 19100762]
  23. Vaccine. 2010 Jan 22;28(4):989-95 [PMID: 19925899]
  24. CA Cancer J Clin. 2007 Jan-Feb;57(1):7-28 [PMID: 17237032]
  25. Health Serv Res. 2000 Apr;35(1 Pt 2):187-206 [PMID: 10778809]
  26. MMWR Morb Mortal Wkly Rep. 2013 Jul 26;62(29):591-5 [PMID: 23884346]
  27. J Adolesc Health. 2010 Oct;47(4):381-8 [PMID: 20864008]
  28. Am J Prev Med. 2012 Jan;42(1):44-52 [PMID: 22176845]
  29. Pediatrics. 2013 Apr;131(4):645-51 [PMID: 23509163]
  30. Vaccine. 2011 Jan 10;29(3):528-34 [PMID: 21050904]
  31. Vaccine. 2012 May 21;30(24):3546-56 [PMID: 22480928]
  32. Issue Brief (Commonw Fund). 2005 Sep;(855):1-12 [PMID: 16180284]
  33. Vaccine. 2011 May 12;29(21):3767-72 [PMID: 21440038]
  34. Med Care Res Rev. 2008 Aug;65(4):450-77 [PMID: 18490702]
  35. Prev Med. 2011 Jun;52(6):456-8 [PMID: 21539853]
  36. Am J Public Health. 2010 Sep;100(9):1630-4 [PMID: 20634466]
  37. J Am Board Fam Med. 2012 Jan-Feb;25(1):42-9 [PMID: 22218623]
  38. Prev Med. 2011 May;52(5):398-400 [PMID: 21108962]
  39. J Am Board Fam Med. 2011 Sep-Oct;24(5):597-604 [PMID: 21900444]

MeSH Term

Adolescent
Adult
Age Factors
California
Child
Electronic Health Records
Female
Humans
Insurance Coverage
Insurance, Health
Oregon
Papillomavirus Vaccines
Patient Acceptance of Health Care
Retrospective Studies
Safety-net Providers
Socioeconomic Factors
Young Adult

Chemicals

Papillomavirus Vaccines

Word Cloud

Created with Highcharts 10.0.0vaccineinsurancehealthHPVuptakepatientsinsuredexaminedcontinuityhumanpapillomavirusfederallyqualifiedFQHCselectronicrecordagedyearscoveragestudyperiodrace/ethnicityageseriescompletionlessInsuranceOBJECTIVES:associationnetworkclinicsMETHODS:analyzedretrospectivedatafemales9-2620082010Basedinformationcategorizedpercenttime0%1%-32%33%-65%66%-99%100%usedbilevelmultivariablePoissonregressioncomparevaccine-initiationprevalencegroupsstratifiedalsoamonginitiatorsleast12monthscomplete3dosesRESULTS:SignificantinteractionsobservedcategoryJuxtaposedcontinuouslypeerslikelyinitiate66%13olderidentifiedracial/ethnicminorityassociatedCONCLUSIONS:DisparitiesstatuspresentstudieddespitefactvaccinesavailablemanyregardlessabilitypayOregonCaliforniacenters

Similar Articles

Cited By